Schering-Plough Corp. (SGP) is in the Pharma Industry

• Sort by
• View Related Content by Tag

• Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit Against Schering-Plough Corporation

  SAN DIEGO -- Coughlin Stoia Geller Rudman & Robbins LLP ("Coughlin Stoia") (http://www.csgrr.com/cases/schering/) today announced that a class action has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Schering-Plough Corporation ("Schering-Plough") (NYSE:SGP) securities during the period between July 24,...

  Research articles 2008-02-22

  Tags: class action, class action suit, Schering-Plough Corp.

• Spector, Roseman & Kodroff, P.C. Files Class Action Suit Against Schering-Plough, Upsher-Smith Laboratories, and American Home Products

  Business Editors/Legal Writers

  Research articles 2001-04-10

  Tags: class action, class action suit, Schering-Plough Corp.

• Cohen, Milstein, Hausfeld & Toll, P.L.L.C. Files Class Action Suit Against Schering-Plough Corporation

  Business Editors/Legal Writers

  Research articles 2001-03-09

  Tags: class action, class action suit, Schering-Plough Corp.

• Law Firm Milberg Weiss Announces Class Action Suit Against Schering-Plough Corporation

  Business Editors & Legal Writers

  Research articles 2001-02-16

  Tags: class action, class action suit, Schering-Plough Corp.

Additional Resources

• Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

  Company reaffirms its innovation leadership and long-term commitment to hepatitis research KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company believes boceprevir has the...

  Articles 2008-11-24

• Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects

  KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Leaders of Schering-Plough Corporation today provided an update for investors on the company's research pipeline, highlighting a rich and innovative portfolio that includes 46 new entities in clinical trials or under regulatory review and 29 in preclinical studies. "Research and...

  Articles 2008-11-24

• Schering-Plough Unveils Top-Line Study Results for SAPHRIS™ Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention

  Company's R&D Update Today Unveils Rich Development Pipeline of Compounds Meeting Important Medical Needs KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today revealed top-line results of a long-term Phase III clinical study of its psychopharmacologic agent SAPHRISTM asenapine demonstrating efficacy and safety in preventing relapse...

  Articles 2008-11-24

• Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease

  KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson's disease experiencing motor fluctuations and abnormal involuntary movements dyskinesias. The...

  Articles 2008-11-24

• Dr. Etienne Gagnon Receives CIHR BIOTECanada/Schering-Plough Canada Fellowship for Innovative Cancer Research

  OTTAWA -- BIOTECanada and Schering Plough Canada are proud to congratulate Dr. Etienne Gagnon of Harvard Medical School on winning this year's Canadian Institutes for Health Research BIOTECanada/Schering-Plough Canada Fellowship. Dr. Gagnon's research is improving our understanding of the physical process behind T cell activation to one day...

  Articles 2008-11-20

• Uptake of Next-Generation Antifungals Has Intensified Competition in the Severe Fungal Infections Drug Market

  However, Generic Erosion and a Dearth of Promising Emerging Therapies Will Result in Modest Annual Growth, According to a New Report from Decision Resources WALTHAM, Mass., Nov. 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds...

  Articles 2008-11-19

• PDI Names Veronica A. Lubatkin to Board of Directors

  SADDLE RIVER, N.J. -- PDI, Inc. (NASDAQ: PDII), a pioneer in providing contract sales and commercial services to the biopharmaceutical industry, today announced the appointment of Veronica Lubatkin, CPA, 45, to the Company's board of directors, effective November 18, 2008. Ms. Lubatkin's appointment expands the number of board members to...

  Articles 2008-11-19

• Redpoint Bio Signs Pharmaceutical Research Agreement with Schering Corporation

  Redpoint Bio and the Schering-Plough Research Institute division of Schering Corporation to Collaborate on Taste Science Research for Pharmaceuticals EWING, N.J. -- Redpoint Bio Corporation (OTCBB: RPBC), a company developing products and technologies to improve the taste of pharmaceutical, food and beverage products, today announced that it has...

  Articles 2008-11-13

• Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance

  BASKING RIDGE, N.J. and DURHAM, N.C., Nov. 11 /PRNewswire/ -- Regado Biosciences, Inc., today announced the appointment of Alexander R. Giaquinto, Ph.D., to the newly created position of Senior Vice President of Regulatory Affairs and Quality Assurance, effective immediately. Dr. Giaquinto brings to Regado over 35 years of...

  Articles 2008-11-11

• Seven Summits Research Releases Alerts on RIMM, JPM, SGP, BG, and MR

  CHICAGO, Nov. 11 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for key stocks. Seven Summits Strategic Investments' PriceWatch Alerts are available at http://www.iotogo.com/s/111108A (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts...

  Articles 2008-11-11

• Schering-Plough to Webcast R&D Update Meeting

  KENILWORTH, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Schering-Plough Corporation will webcast its "R&D Update" meeting for analysts and portfolio managers being held on Monday, Nov. 24, 2008. Fred Hassan, Schering-Plough's chairman and CEO, Tom Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute, and other members of...

  Articles 2008-11-07

• Promotion of Merck/Schering-Plough's Vytorin as a First-Line Agent has been Compromised by Negative Press

  Lipitor's Abstract Tagline Fails to Resonate with Physicians, According to a New Report from Decision Resources WALTHAM, Mass., Nov. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Merck/Schering-Plough's promotion of Vytorin as a...

  Articles 2008-11-06

• Physicians Rank Schering-Plough's Marketing Messages for Asmanex as the Most Appealing in the Asthma Drug Market

  Patients Respond Most Favorably to the Marketing Messages for Advair and Xolair, According to a New Report from Decision Resources WALTHAM, Mass., Nov. 5 /PRNewswire/ -- Decision Resources one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that physicians and...

  Articles 2008-11-05

• Schering-Plough Corp., Missouri settle suit for $31M

  The Missouri Attorney General's Office has reached a $31 million settlement with Schering-Plough Corp. The settlement was reached on Friday after jurors unanimously ruled against the pharmaceutical company Thursday and awarded $7.3 million in compensatory damages to the state. "The jury came back on...

  Articles 2008-11-03

• Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

  Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today reported that a planned interim analysis of a Phase...

  Articles 2008-11-01

• Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case

  ST. LOUIS, Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corporation said today that it strongly believes that the decision reached by a jury in Missouri related to reimbursement by Missouri's Medicaid program of certain products sold by Warrick Pharmaceuticals, the company's former generics subsidiary, was incorrect. The company said it...

  Articles 2008-10-30